ערך בספרים למניה: Virios (VIRI)

Virios Therapeutics is implementing breakthrough methods to combat viral infections, protecting its developments with strict patents and rigorous FDA control. The book value per share reflects capital accumulation dynamics, where the level of 0.11 represents the current value. The monopoly potential in fibromyalgia therapy is supported by a flexible virtual manufacturing model that relies on the capacities of external contract partners.

For Virios Therapeutics (VIRI), whose stability depends on the import of components from Asia, the book value per common share serves as an indicator of the actual net asset value per business unit. The current value of 0.11 reflects the remaining equity minus liabilities, allowing an investor to assess the company's intrinsic value and the risks of asset undervaluation amid geopolitical instability.